FPI selling slows down in November

After selling aggressively for over a month, foreign portfolio investors (FPIs) have slowed down in November, as the ‘sell-India-buy-China’ theme does not seem to be playing out as it was anticipated earlier. In addition, the initial euphoria of Donald Trump’s victory in the US elections seems to be waning, as they would prefer to wait for his policy decisions in January.

So far in November, they have sold shares worth Rs 25,942 crore ($3.08 billion)—less than one-third of the Rs 94,017 crore ($11.18 billion) they sold in October.

“…it is expected that FIIs will reduce their selling as we near the end of the calendar year. Fresh allocations or significant investments are likely to occur once there is greater clarity regarding the Trump administration’s policies,” said Vipul Bhowar, senior director of listed investments at Waterfield Advisors.

Also ReadIPOs wait for visibility as fog deepens

While experts agree that the recent escalation in the Ukraine-Russia war could change things suddenly, like the sell wave that came in the last hour of Tuesday’s trading when FIIs sold shares of Rs 3,411 crore, most believe that the earnings disappointment has been more or less priced in.

Since late September, the selling activity has been an effect of high valuations in India, coupled with weak quarterly earnings. Global factors such as Trump’s victory, rising US bond yields, geopolitical tensions in the Middle East, and attractive valuations in China have also been weighing on Indian equities, said market analysts.

“The relentless FPI selling has been triggered by the cumulative impact of three factors: one, the high valuations in India; two, concerns regarding the earnings downgrade; and three, the Trump trade,” said V K Vijayakumar, chief investment strategist at Geojit Financial Services.

In the November fortnight, financial services and oil & gas stocks continued to be the hardest hit, while sectors such as information technology, construction, and healthcare managed to see some inflows during the first fortnight of the month, according to NSDL data.

FPIs pulled out Rs 7,092 crore ($840 million) from financial services stocks, including banks, and Rs 7,214 crore ($855 million) from shares of oil & gas companies. Automobile and fast-moving consumer goods (FMCG) companies also saw withdrawals of Rs 4,411 crore ($523) and Rs 3,589 crore ($425),

 » Read More

Related Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

‘Pramerica Life targets Rs 3,000-crore GWP in FY26,’ Pankaj Gupta

Pramerica Life Insurance, a joint venture between subsidiaries of Piramal Capital and Housing Finance and US-based Prudential Financial Inc, aims to close FY26 with Rs 3,000 crore in gross written premium. In an interview with Narayanan V, managing director and CEO Pankaj Gupta discusses the products and distribution strategy. Excerpts: Life insurance premiums have been

Tata small cap fund: Targeting growth at reasonable valuations

Tata Small Cap Fund is a growth-oriented scheme in the Small Cap Fund category that has exhibited a noteworthy track record since its inception and has outpaced many of its prominent peers, thereby rewarding investors with superior risk-adjusted returns. Launched in November 2018, Tata Small Cap Fund aims to invest in stocks of companies that are in growth